The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe's pharma companies tap into fast-growing global markets.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh